Viking Therapeutics Gains Momentum as Rival Faces Setback
Published on 01/18/2026 at 06:54 | Redaktion boerse-global.de
Shares of Viking Therapeutics closed the week on a strong note, propelled by emerging challenges facing a major competitor in the obesity drug market. After a weaker performance earlier in the week, the stock reversed course sharply on Friday, climbing 6.4% to close at $33.92. This surge was triggered by reports indicating a potential delay for a key obesity treatment from Eli Lilly, prompting a market reassessment of Viking’s prospects within the competitive GLP-1 segment.
This price action builds upon the already heightened investor interest in mid-cap biotechnology firms with promising pipeline assets. The critical question now is whether Viking can validate this increased optimism with continued clinical progress.
The Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
